Saw this from "polo_grill" a long term accurate poster on IV with ties to institutions - he says institutions say approvals this week worth $10-$20 on price per share...Added
EU Approval - Major Event not just a normal milestone. PPS will move much higher.
As the market and Street absorbs this news look for a major move in PPS. Those who recall REV approval know the drill. Starts out slowly in the PM and moves much higher as the day move on as buyers and shorts do what they do best. Buy more, and buy to cover.
I particularly like the low key nature of the announcement for a long awaited event. Just spoke to a tute who has follow the EU approval saga for over 5 years. Worth 10-20 points PPS in their opinion. looking forward to a great day. We have some short interest trapped. Most tutes can NOT touch the PM by their own trading rules. Summit should buy and add to what will be an increasing PPS. Other drugs also doing well, team working hard, and metrics make this a cheap price in the 120's.
What is amazing is RJ Kirk has again CLEARLY ARTICULATED deal and data is coming and just like Q3 call there are some who have not done enough due diligence and doubt this great investor and great mind....he has come through for investors time and time again with Clinical Data, Scios, New River, etc and now has come through for ZIOP investors and this he is telling you is ONLY THE BEGINNING. I pity the fools who are not paying attention. ZIOP is headed to the teens soon and 20s by summer. GET IN NOW